Data from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/24/2026 | $60.00 → $80.00 | Hold | Jefferies | |
| 4/24/2026 | $48.00 → $56.00 | Underperform | BofA Securities | |
| 4/24/2026 | $50.00 → $75.00 | Neutral | Robert W. Baird | |
| 4/24/2026 | $35.00 → $45.00 | Underweight | Analyst | |
| 4/24/2026 | $70.00 → $110.00 | Overweight | KeyBanc Capital Markets | |
| 4/24/2026 | $65.00 → $75.00 | Hold | Stifel | |
| 4/24/2026 | $76.00 → $105.00 | Buy | The Benchmark Company | |
| 4/24/2026 | $48.00 → $80.00 | Sector Perform | RBC Capital Mkts |
6-K - TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (0001046179) (Filer)
10-Q - INTEL CORP (0000050863) (Filer)
IRANNOTICE - INTEL CORP (0000050863) (Filer)
News Summary First-quarter revenue was $13.6 billion, up 7% year-over-year (YoY). First-quarter earnings (loss) per share (EPS) attributable to Intel was $(0.73); non-GAAP EPS attributable to Intel was $0.29. Forecasting second-quarter 2026 revenue of $13.8 billion to $14.8 billion; expecting second-quarter EPS attributable to Intel of $0.08 and non-GAAP EPS attributable to Intel of $0.20. Intel Corporation today reported first-quarter 2026 financial results. "The next wave of AI will bring intelligence closer to the end user, moving from foundational models to inference to agentic. This shift is significantly increasing the need for Intel's CPUs and wafer and advanced packagi
AUSTIN, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Artificial intelligence is no longer confined to software innovation; it is increasingly becoming an energy-intensive phenomenon. As AI systems grow in size and sophistication, the computational requirements needed to train and run them are triggering a sharp rise in electricity consumption, one that is beginning to strain existing infrastructure. Data centers, once considered purely digital enablers, are now among the most power-demanding assets in the global economy. This evolution is prompting governments, utilities and private enterprises alike to reassess a critical constraint: the limiting factor in AI's
Revenue of $558 million in the first quarter increased 27% year over year compared to Q1 2025. We are raising the midpoint of our full-year 2026 revenue guidance by 2% to reflect better-than-expected demand in the first quarter. Diluted EPS (GAAP) was $(4.68) and Adjusted Diluted EPS (Non-GAAP) was $0.12 in the first quarter. GAAP Operating Loss was impacted by a non-cash goodwill impairment of $3,788 million related to the goodwill asset on Mobileye's balance sheet resulting from Intel's acquisition of Mobileye in 2017. Generated $75 million of operating cash flow in the first quarter of 2026. The acquisition of Mentee Robotics Ltd. ("Mentee Robotics") closed in early February, r
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
4 - BOEING CO (0000012927) (Issuer)
4 - INTEL CORP (0000050863) (Issuer)
4 - BOEING CO (0000012927) (Issuer)
4 - TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (0001046179) (Issuer)
4 - Tesla, Inc. (0001318605) (Issuer)
Jefferies reiterated coverage of Intel with a rating of Hold and set a new price target of $80.00 from $60.00 previously
BofA Securities reiterated coverage of Intel with a rating of Underperform and set a new price target of $56.00 from $48.00 previously
Robert W. Baird reiterated coverage of Intel with a rating of Neutral and set a new price target of $75.00 from $50.00 previously
Nvidia's top 1% AI engineer leaves world's most valuable company to lead self-storage's first Chief AI Officer role at 10 FederalRALEIGH, N.C., April 6, 2026 /PRNewswire/ -- 10 Federal, a leading technology-driven self-storage owner and operator, today announced the appointment of Christopher Taylor as its Chief A.I. Officer (CAIO), a newly created executive position that represents the first dedicated C-suite AI role in the self-storage industry. Taylor joins 10 Federal from Nvidia (NASDAQ:NVDA), the global leader in AI computing, where he served as a Senior Software Engineer working across both the data center division and the autonomous vehicle platform, and ranked among the top 1% of AI
Intel Corporation today announced the appointment of Aparna Bawa as EVP, chief legal & people officer. Bawa will report directly to CEO Lip-Bu Tan and will lead Intel's global legal, ethics, compliance, people, and culture organizations as the company accelerates its transformation and execution agenda. "The role of legal and people leadership has never been more critical as Intel drives cultural transformation with discipline, speed, and integrity," said Intel CEO Lip-Bu Tan. "Aparna brings a rare combination of operational rigor, business judgment, and people-first leadership. Her experience helping scale global technology companies through periods of significant change will be invaluab
Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi
Revenue of $558 million in the first quarter increased 27% year over year compared to Q1 2025. We are raising the midpoint of our full-year 2026 revenue guidance by 2% to reflect better-than-expected demand in the first quarter. Diluted EPS (GAAP) was $(4.68) and Adjusted Diluted EPS (Non-GAAP) was $0.12 in the first quarter. GAAP Operating Loss was impacted by a non-cash goodwill impairment of $3,788 million related to the goodwill asset on Mobileye's balance sheet resulting from Intel's acquisition of Mobileye in 2017. Generated $75 million of operating cash flow in the first quarter of 2026. The acquisition of Mentee Robotics Ltd. ("Mentee Robotics") closed in early February, r
Mobileye Global Inc. (NASDAQ:MBLY) today announced its Board of Directors has authorized a program to repurchase up to $250 million of Mobileye's outstanding Class A common stock (the "Repurchase Program"). The share repurchase program demonstrates both the leadership team and Board of Directors' confidence in the Company's current products as well as its position as a leader in the development and deployment of advanced driver assistance systems, autonomous driving solutions, and complex physical AI systems at scale. The Repurchase Program is intended to partially offset dilution associated with share-based compensation and shares issued in connection with the Mentee Robotics acquisition
ARLINGTON, Va., April 22, 2026 /PRNewswire/ -- First Quarter 2026Revenue increased to $22.2 billion primarily reflecting 143 commercial deliveriesGAAP loss per share of ($0.11) and core loss per share (non-GAAP)* of ($0.20)Operating cash flow of ($0.2) billion and free cash flow (non-GAAP)* of ($1.5) billionTotal company backlog grew to a record $695 billion, including over 6,100 commercial airplanesTable 1. Summary Financial ResultsFirst Quarter(Dollars in Millions, except per share data)20262025ChangeRevenues$22,217$19,49614 %GAAPEarnings from operations$448$461(3) %Operating margins2.0 %2.4 %(0.4) PtsNet loss($7)($31)NMDiluted loss per share($0.11)($0.16)NMOperating cash flow($179)($1,61
SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)